NervGen Pharma (NGENF)
OTHER OTC:NGENF

NervGen Pharma (NGENF) Financial Statements

42 Followers

NervGen Pharma Financial Overview

NervGen Pharma's market cap is currently ―. The company's EPS TTM is $-0.248; its P/E ratio is -8.28; NervGen Pharma is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-0.07. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBITC$ -8.61MC$ -4.30MC$ -4.76MC$ -4.71MC$ -7.94M
EBITDAC$ -8.57MC$ -4.27MC$ -4.73MC$ -4.67M-
Net Income Common StockholdersC$ -8.61MC$ -4.30MC$ -4.76MC$ -4.71M-
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsC$ 11.66MC$ 14.79MC$ 16.08MC$ 18.02MC$ 22.45M
Total AssetsC$ 13.24MC$ 16.36MC$ 17.42MC$ 19.10MC$ 23.88M
Total DebtC$ 197.19KC$ 219.24KC$ 240.97KC$ 262.37KC$ 283.45K
Net DebtC$ -11.46MC$ -14.57MC$ -15.84MC$ -17.76MC$ -22.17M
Total LiabilitiesC$ 15.25MC$ 11.25MC$ 9.86MC$ 9.22MC$ 10.41M
Stockholders EquityC$ -2.01MC$ 5.11MC$ 7.56MC$ 9.88MC$ 13.46M
Cash Flow-
Free Cash FlowC$ -3.09MC$ -1.57MC$ -2.00MC$ -4.78MC$ -5.15M
Operating Cash FlowC$ -3.09MC$ -1.43MC$ -2.00MC$ -4.78M-
Investing Cash FlowC$ 1.00C$ -138.46KC$ -2.94KC$ 2.55K-
Financing Cash FlowC$ 74.77KC$ 72.38KC$ 253.86KC$ 365.27K-
Currency in CAD

NervGen Pharma Earnings and Revenue History

NervGen Pharma Debt to Assets

NervGen Pharma Cash Flow

NervGen Pharma Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis